Vancouver, BC — January 7, 2026 — Leads & Copy — Ovation Science Inc. (CSE:OVAT)(OTC PINK:OVATF) has announced the issuance of a new Canadian patent for its proprietary topical formulations containing CBD and THC.
The patent, entitled “Composition and method for transdermal delivery of cannabidiol (CBD) and delta9-tetrahydrocannabinol (THC),” expands Ovation’s intellectual property protection beyond its previously issued U.S. patent. This strengthens the Company’s international patent portfolio.
With patents secured in both the United States and Canada, Ovation is positioned to pursue exclusive licensing agreements, strategic partnerships, and product commercialization across two of the largest regulated cannabis markets.
Ovation’s patented transdermal cannabinoid formulations are designed to efficiently deliver cannabinoids through the skin and into systemic circulation. These formulations use Ovation’s Invisicare® drug delivery technology, which has demonstrated enhanced cannabinoid absorption compared to conventional topical/transdermal products.
Terry Howlett, President of Ovation Science, stated that the patent represents a value-creation milestone for Ovation, its shareholders, and licensees. Howlett added that securing Canadian patent protection strengthens their defensible IP position and increases the attractiveness of their technology to potential licensees. He believes Ovation is uniquely positioned to capitalize on growing demand for effective topical cannabinoid solutions, particularly with the potential rescheduling of cannabis to Schedule 3 in the USA.
Ovation’s Invisicare technology is designed for scalability across multiple active ingredients, delivery formats, and regulated markets. In addition to Ovation’s current cannabis formulations, Invisicare offers potential expansion into wellness, pharmaceutical, other transdermal product categories and topical beauty products, all using cannabinoids. The company says this creates multiple avenues for future growth, licensing revenue, and shareholder value creation.
Comparative studies showed Ovation’s products achieved CBD bioavailability of up to 82%, compared to 2-3% for competing transdermal products. Oral CBD products, such as gummies, typically exhibit a low bioavailability of approximately 6%, as a significant portion of the CBD is lost during first-pass metabolism in the liver. Ovation’s Invisicare® formulations are designed to overcome challenges related to CBD’s poor water solubility and limited stability.
Ovation Science Inc. develops topical and transdermal CBD/THC and other cannabinoid products which are out-licensed to licensed operators by state or country. Ovation also distributes topical CBD products under Ovation’s own brands; ARLO CBD Beauty and InVibe® MD (“wellness” line); all powered by its patented Invisicare® skin delivery technology. Ovation earns revenues from royalties on licensees’ sales and the sale of Invisicare, along with revenue from its own product sales. Ovation has offices in Vancouver, Canada and Las Vegas, USA.
Doreen McMorran: info@ovationscience.com PH: 604-982-5700
Source: Ovation Science Inc.
